Jerold Share, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1851350508
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,961 of the $7,173 with a category attached, or 69.2%. 19 manufacturers reported payments, led by Corcept Therapeutics at 38.0% of the total. Reporting peaked in 2019 at $2,340 and has fallen 85.6% since, to $337 in 2024.
Across 231 payments — averaging $31.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$3K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Amneal Pharmaceuticals LLC$717
- Sanofi-aventis U.S. LLC$367
- Xeris Pharmaceuticals, Inc.$232
- plus $937 from 13 others
What the payments were for
- Consulting fees$93013%
- Speaking & faculty fees$1,22517%
- Food & beverage$4,96169%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 66 | $2,723 |
| Lilly USA, LLC | 54 | $1,189 |
| AstraZeneca | 3 | $1,007 |
| Amneal Pharmaceuticals LLC | 38 | $717 |
| Sanofi-aventis U.S. LLC | 2 | $367 |
| Xeris Pharmaceuticals, Inc. | 11 | $232 |
| Novo Nordisk | 12 | $230 |
| Mannkind Corporation | 9 | $173 |
| Merck | 17 | $155 |
| Medtronic | 2 | $65 |
| Abbott | 3 | $53 |
| Amgen | 2 | $53 |
| AbbVie | 3 | $51 |
| Antares Pharma, Inc. | 2 | $42 |
| Novartis | 2 | $36 |
| Therapeuticsmd, Inc. | 2 | $27 |
| Radius Health, Inc. | 1 | $23 |
| IBSA Pharma Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,107
- FARXIGA$930
- SOLIQUA 100/33$350
How this compares
$7,173 in reported general payments places this provider in the 75th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 107 | $142,399 |
| OzempicSemaglutide | 68 | $89,589 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $71,563 |
| TrulicityDulaglutide | 26 | $48,087 |
| RybelsusSemaglutide | 17 | $26,135 |
| JanuviaSitagliptin Phosphate | 21 | $20,344 |
| JardianceEmpagliflozin | 16 | $17,518 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 24 | $17,431 |
| SynthroidLevothyroxine Sodium | 72 | $8,169 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 13 | $6,298 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,516 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,084 |
| Levemir FlexpenInsulin Detemir | 14 | $2,618 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 21 | $1,641 |
| Liothyronine Sodium | 20 | $1,408 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,189 | $190,486133 claims |
| Novo NordiskOzempic, Rybelsus | $230 | $115,72485 claims |
| MerckJanuvia, Janumet Xr, Janumet | $155 | $43,29156 claims |
| AbbVieSynthroid | $51 | $8,16972 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $717 | $45936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.